Rich Aldrich, MBA

MRich Aldrich, MBAr. Aldrich is co-founder and General Partner of Longwood Fund and has spent approximately 35 years as a life sciences entrepreneur and investor. Mr. Aldrich co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline); Concert Pharmaceuticals NASDAQ: CNCE), where he serves as Chair of the Board; and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), Axial Biotherapeutics, and TScan Therapeutics. Mr. Aldrich also serves as a Director of Longwood portfolio companies Axial, Renovia, and Sitryx Therapeutics.

Prior to co-founding Longwood, Mr. Aldrich co-founded RA Capital Management, LLC, a life sciences investment fund, in which he remains an investor. Prior to founding RA Capital Management, LLC, Mr. Aldrich was a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX), a $45 billion company, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to Vertex, Mr. Aldrich held several management positions at Biogen Inc.

Mr. Aldrich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth College.

David H. Donabedian, Ph.D.

DDavid H. Donabedian, Ph.D.r. Donabedian is a Venture Partner at Longwood Fund and Chief Executive Officer and co-founder of Longwood portfolio company Axial Biotherapeutics. Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience and a track record of building companies. Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GlaxoSmithKline (NYSE: GSK). At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture's Strategic Services Consulting Group.

Dr. Donabedian holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.

Lea Hachigian, Ph.D.

DLea Hachigian, Ph.D.r. Hachigian is a Principal at Longwood Fund and President and co-founder of Longwood portfolio company Immunitas Therapeutics and served as co-founder and President of Longwood-founded TScan Therapeutics. She received her Ph.D. from MIT in molecular and cellular neuroscience where she was a NSF Graduate Research Fellow. As a graduate student in the Heiman Lab at the Broad Institute, Dr. Hachigian studied the determinants of neuronal identity and vulnerability in disease. Prior to her doctorate, Dr. Hachigian received an A.B. from Harvard University where she graduated magna cum laude with high honors in Neurobiology and received a certificate in Mind Brain and Behavior. While at Harvard, Dr. Hachigian researched genetic models of developmental disorders in the Fagiolini/Hensch lab at Children's Hospital/Harvard Medical School. She has received numerous fellowships for her research and multiple teaching awards for her work with both undergraduate and graduate students. Dr. Hachigian was named to the Forbes 30 Under 30 list for healthcare for her work in co-founding TScan Therapeutics. 

Arielle Jackson

MArielle Jacksons. Jackson is the Director of Investor Relations at Longwood Fund.  Ms. Jackson has ten years of marketing and communications experience and has worked closely with key biopharma thought leaders and Christoph Westphal in numerous capacities.  Ms. Jackson received a BBA degree with high honors from the Isenberg School of Management at the University of Massachusetts at Amherst.  She also completed coursework at Amherst College and Harvard and received a certificate in International Relations from Mount Holyoke College.

John Lawrence, MBA, CPA

MJohn Lawrence, MBA, CPAr. Lawrence is the Chief Financial Officer of Longwood Fund. He has experience as partner and CFO of Longworth Venture Partners managing the firm’s financial, legal, and administrative functions and has been active with many of the finance and operating initiatives of their portfolio companies. Prior to Longworth, Mr. Lawrence served as the CFO and member of the Board of Directors of Quail Piping Products, Inc. Mr. Lawrence helped form Quail in 1999 after raising over $20 million in equity and debt financing to orchestrate a management-led buyout of the company from its then-publicly traded parent company. Prior to Quail, Mr. Lawrence was the Assistant Vice President of Finance of Asahi/America, Inc., a NASDAQ-listed manufacturer and distributor of fluid flow systems. At Asahi, Mr. Lawrence led all finance, accounting, M&A, SEC, and IR activities. Mr. Lawrence began his career at Arthur Andersen LLP holding various senior audit positions in the Enterprise and Technology Group. Mr. Lawrence is a member of the Private Equity CFO Association where he serves as a member of their Board of Directors and the Financial Executives Networking Group. A Certified Public Accountant, Mr. Lawrence earned his MBA from Suffolk University and his BA in accounting from Assumption College.

James Mutamba, Ph.D.

DJames Mutamba, Ph.D.r. Mutamba is a Principal at Longwood Fund. Prior to Longwood, he was a Senior Associate at PureTech Health and co-founded Commense, Inc., a microbiome-based maternal and childhood health company. Dr. Mutamba was also a co-founder and inventor in Glyph Biosciences, an immune-focused company targeting novel lymphatic system biology, and Calix Biopharma, a company developing engineered exosomes for novel drug delivery applications. Prior to joining PureTech, Dr. Mutamba was a strategy consultant at ClearView Healthcare Partners and played multiple roles in research and product development at Pathogenica, Inc., a biotech startup out of Harvard University. Dr. Mutamba earned his Ph.D. from MIT in the Department of Biological Engineering with his thesis work focusing on the relationship between inflammation-derived reactive species and cancer. He also completed coursework at the MIT Sloan School of Management. Dr. Mutamba received his B.S. in Biochemistry from UNCG where he graduated summa cum laude and Phi Beta Kappa.

Aleks Radovic-Moreno, Ph.D.

DAleks Radovic-Moreno, Ph.D.r. Radovic-Moreno is an Entrepreneur-in-Residence at Longwood Fund, where he is involved in building and supporting portfolio companies. He was previously Senior Vice President at PureTech Health (LSE: PRTC), where he was a co-founder and member of the senior leadership team of several portfolio companies. Dr. Radovic-Moreno was a co-founder of Vor Biopharma, a company developing novel engineered hematopoietic stem cell therapies for treating blood cancers. At Vor, Dr. Radovic-Moreno led a fundraising effort that culminated in a $42M Series A financing led by 5AM Ventures & RA Capital in 2019. He also co-founded and acted as interim CEO of Alivio Therapeutics, a company focused on developing new therapies for autoimmune and inflammatory diseases based on a new category of inflammation-targeting drugs. He was previously a scientist at Exicure, where he was the lead inventor of AST-008, a TLR9 agonist now in phase 2 trials for treating various solid tumors. Dr. Radovic-Moreno completed his graduate work as an NSF Fellow in Robert Langer's lab at MIT, where he developed novel strategies for managing bacterial infections, including a novel vaccine candidate for chlamydia infections. Dr. Radovic-Moreno was awarded the Alumni Achievement Award by the Pennsylvania State University for extraordinary professional accomplishment by graduates under the age of 35. Dr. Radovic-Moreno received his B.S. in Chemical Engineering from the Pennsylvania State University and PhD in Chemical and Biomedical Engineering from MIT and the Harvard-MIT Division of Health Sciences & Technology.

David Steinberg, MBA

MDavid Steinberg, MBAr. Steinberg is a General Partner at Longwood Fund and Chief Executive Officer and co-founder of Longwood portfolio company Pyxis Oncology. He joins from PureTech Health, (LSE: PRTC), a biotech incubator which he co-founded and served as Chief Innovation Officer, focusing on venture creation, investing, and launching innovative biotech companies. Mr. Steinberg was the co-founder and CEO of several biotech companies, including Longwood-founded Pyxis Oncology, Vedanta Biosciences, Calix, Vor Biopharma, and was co-founder of Restorbio (NASDAQ: TORC). He previously worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and R&D at P&G Pharmaceuticals. He received his MBA in strategy and finance from the University of Chicago Booth School of Business and holds a BA in biology from Cornell University. 

Christoph Westphal, M.D., Ph.D.

DChristoph Westphal, M.D., Ph.D.r. Westphal is co-founder and General Partner of Longwood Fund, Chair of TScan Therapeutics, Chair of Immunitas Therapeutics, and has spent 20 years as a life sciences CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of six biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $16 billion and have developed and received FDA approval for important drugs. These include: These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), and Verastem (NASDAQ: VSTM). Dr. Westphal is also co-founder of Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly), Axial Biotherapeutics, TScan Therapeutics, Immunitas Therapeutics and Pyxis Oncology; and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE). Companies founded by Dr. Westphal have created over 2,000 jobs in the Boston area.

Companies founded by Dr. Westphal have developed and received FDA approval for important drugs, including the first RNAi therapy; for currently incurable cancers; the largest-selling heparin in the United States; a therapy for MS; for Beta Thalassemia and Myelodysplastic Syndrome; and several experimental medicines: for cystic fibrosis (phase 3), for serious inflammatory disorders (phase 2), and for serious neurological illnesses such as ALS and MS (positive phase 2).

Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra; he is also in the ownership group of the Boston Celtics. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has been featured on 60 Minutes with Morley Safer, CNN’s Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of Fortune, New York Times, and Wall Street Journal cover articles. Dr. Westphal has generally avoided media interviews since 2010.


Strategic Advisory Board

Jean-Jacques Bienaimé
Chair & CEO, BioMarin; Director, BIO

James Foster
Chair, President and CEO, Charles River Laboratories

Wyc Grousbeck
Managing Partner and CEO, Boston Celtics

Laurie Glimcher, MD
President & CEO, Dana-Farber Cancer Institute; Harvard

Peter Hutt, LLB, LLM
Former FDA GC; SAB: Sirtris (NASDAQ: SIRT, now GSK), Alnara, Axial; BOD: Momenta, Concert (NASDAQ: MNTA, CNCE)

Rod MacKinnon, PhD
Nobel Laureate; Rockefeller University

John Maraganore, PhD
CEO, Alnylam (NASDAQ: ALNY); Chair Emeritus, BIO

James C. Mullen
Chair, Editas; Former CEO, Biogen

Elizabeth Nabel, MD
President, Brigham Health

Al Sandrock, MD, PhD
EVP & CMO, Biogen

Paul Schimmel, PhD
NAS; Scripps; Co-Founder, Alnylam, Momenta, Sirtris (NASDAQ: ALNY; MNTA; SIRT, now GSK)

Phil Sharp, PhD
Nobel Prize; NAS; Co-Founder, Biogen, Alnylam (NASDAQ: BIIB, ALNY); SAB: Sirtris, Verastem (NASDAQ: SIRT, now GSK; VSTM)

Henri Termeer (in memoriam)
Former Chair, President and CEO, Genzyme

Roger Tung, PhD
Co-Founder, President & CEO, Concert Pharmaceuticals (NASDAQ: CNCE)

Chris Walsh, PhD
Harvard; NAS; Genzyme; SAB, Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM), TScan

Susan Windham-Bannister, PhD
Managing Partner, Biomedical Innovation Advisors; President Emeritus, Massachusetts Life Sciences Center

K. Dane Wittrup, PhD
MIT, Koch; Scientific Founder: Immunitas

Kai Wucherpfennig, MD, PhD
Chair, Cancer Immunology & Virology, Dana-Farber Cancer Institute; Harvard, Broad; Scientific Founder: Immunitas; SAB: TScan